Navigation Links
Psoriasis Cure Now launches StimulateResearch.com to Ensure That Medical Research is Part of Stimulus Bill
Date:2/6/2009

KENSINGTON, Md., Feb. 6 /PRNewswire-USNewswire/ -- "Psoriasis Cure Now," a nonprofit patient advocacy organization, has launched a micro-Web site, www.StimulateResearch.com, to help everyday Americans interested in medical research be heard in the stimulus debate that has been dominated by powerful lobbyists and special interests. The Web site allows people to write their lawmakers urging them to make biomedical research a meaningful part of any stimulus bill that emerges in the coming days. The nearly $1 trillion bill sweeping through Congress could crowd out medical research funding at the National Institutes of Health (NIH) for years to come.

"This is the fastest I have seen Washington allocate $1 trillion in my quarter century following politics," said Michael Paranzino, president of Psoriasis Cure Now. "It seems to have caught the patient advocacy community flat-footed. But medical research is every bit as 'shovel ready' and 'stimulative' as Austin's proposed Frisbee golf course or the projects Chicago won't even disclose. Dollars wasted now will not cure cancer, arthritis or psoriasis tomorrow. Our Web site lets Americans concerned about curing disease make sure medical research is not neglected as the final stimulus package is hammered out in the coming week."

The House-passed stimulus bill includes a few billion for NIH (much of it to build new buildings), and the current Senate version includes $10 billion for NIH over two years. But a bipartisan group of Senators is looking to cut more than $100 billion from the current version, and the House-Senate Conference Committee is expected to make significant additional revisions, meaning the fate of medical research is highly uncertain. For the last five years, NIH funding has been stagnant, with thousands of well-designed and 'shovel ready' grant requests by scientists from all 50 states being held up by a lack of funding.

Psoriasis Cure Now takes no position on whether the stimulus bill should pass or fail; rather, it is pointing out that spending $1 trillion in lobbyist-driven spending now could mean that vital NIH research could be starved for years to come. Its www.StimulateResearch.com site is designed to give everyday Americans a chance to be part of this debate as well.

"Silence may be golden when it's time for my kids to go to bed, but silence by patient advocates is definitely not golden during this stimulus debate," Paranzino added. "The asphalt lobbyists, the honey bee lobbyists, the state politician lobbyists --- all are out in force, seeking parts of the one trillion dollars in play. It's essential that people who want cures for AIDS, MS, autism, heart disease and diabetes be heard as well. StimulateResearch.com lets us be heard."

http://www.psoriasis-cure-now.org


'/>"/>
SOURCE Psoriasis Cure Now
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Galderma Wins FDA Approval for Vectical(TM) Ointment, a Novel Topical Therapy for Mild-to-Moderate Plaque Psoriasis
2. Gene Insights May Improve Psoriasis Care
3. Scientists unmask genetic markers associated with psoriasis
4. An Oral Agent for the Treatment of Moderate to Severe Psoriasis Would Earn a Higher Patient Share in the United States than in Europe
5. Obesity-Related Hormone Tied to Psoriasis
6. Medarex to Receive Milestone Payment for Approval of STELARA(TM) (Ustekinumab) for the Treatment of Moderate to Severe Plaque Psoriasis
7. Biologic Drugs, Particularly Centocor/Janssen-Cilags Stelara and Abbott/Eisais Humira, will Drive the Psoriasis Drug Market to $5 Billion by 2017
8. Indigo Ointment Benefits Psoriasis Patients
9. National Psoriasis Foundation Seeks 10,000 Americans to Support Psoriasis Research for World Psoriasis Day
10. National Psoriasis Foundation Releases 2008 Study Results
11. After Fits and Starts, New Hope for Psoriasis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... ... California, committed to raising awareness for Duchenne muscular dystrophy, and funding for ... CAP-1002 (cardiosphere-derived cells) Phase I/II HOPE clinical trial in Duchenne announced today. ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... HR decision-makers are preparing for how his administration could impact the employee benefits ... into what changes are most likely to make it through Congress. His discussion ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... The doctors ... Richmond, BC, who live with dental fear and require sedation to receive dental care. ... at ease during various procedures, from hygienic cleanings to oral surgery, at their dental ...
(Date:4/25/2017)... ... 25, 2017 , ... Patients who would like to straighten ... fraction of the time as traditional braces – Wilckodontics®. Dr. Victoria Chen, an ... this revolutionary treatment with or without a referral. , Wilckodontics is also ...
(Date:4/25/2017)... ... 25, 2017 , ... As Spring reignites vigilance against Zika ... to Zika virus during pregnancy, as well as other prenatal exposures like cocaine, ... , The Teratology Society is an international and multidisciplinary group of ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... DUBLIN , April 20, 2017 ... the "Global Biosimilar Pipeline and Market Prospects: Addressing ... report to their offering. ... "Global Biosimilar Pipeline and Market ... by Design" provides an in-depth assessment of the current ...
(Date:4/20/2017)... Research and Markets has announced the addition ... Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics during ... ... rise from USD 20 Billion in 2015 to around USD 26 ... - Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage ...
(Date:4/20/2017)... , April 20, 2017   ZappRx, Inc ., a ... drug prescribing process, today announced it closed $25 million in ... venture capital firm based in Seattle ... Venture Partners . The Series B round included participation from ... in 2014, and GV (formerly Google Ventures). As ...
Breaking Medicine Technology: